Detalhe da pesquisa
1.
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
N Engl J Med
; 389(22): 2039-2051, 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37870976
2.
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.
Future Oncol
; 18(6): 639-647, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34911336
3.
Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib.
Br J Haematol
; 194(1): 83-91, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33942292
4.
Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
Prostate
; 78(4): 308-317, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29314097
5.
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
N Engl J Med
; 371(21): 1963-71, 2014 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25264305
6.
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.
Invest New Drugs
; 33(5): 1100-7, 2015 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26334219
7.
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
N Engl J Med
; 363(18): 1693-703, 2010 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-20979469
8.
Effects of food and race on the pharmacokinetics of lazertinib in healthy subjects and patients with EGFR mutation-positive advanced non-small cell lung cancer.
Lung Cancer
; 175: 112-120, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36495784
9.
Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial.
Blood Adv
; 7(10): 2008-2017, 2023 05 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36696540
10.
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
J Clin Oncol
; 37(15): 1285-1295, 2019 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30901302
11.
The role of metastasis suppressor genes in metastatic dormancy.
APMIS
; 116(7-8): 586-601, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18834404
12.
Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
J Thorac Oncol
; 11(5): 737-747, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26899759
13.
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
J Clin Oncol
; 33(17): 1881-8, 2015 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-25624436
14.
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
J Clin Oncol
; 30(13): 1527-33, 2012 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22454420
15.
Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis.
Mol Cancer Res
; 7(9): 1438-45, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19723875